Catalyst Pharmaceuticals to Showcase Real?World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
MWN-AI** Summary
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), a biopharmaceutical company dedicated to developing therapies for rare diseases, announced its participation in the 2026 MDA Clinical & Scientific Conference in Orlando, Florida. The company will showcase real-world findings on Duchenne muscular dystrophy (DMD) through various poster presentations and will host a vamorolone-focused symposium alongside Santhera Pharmaceuticals.
The conference provides a valuable platform for Catalyst to underscore the significance of real-world evidence in shaping care for children with DMD. According to Will Andrews, MD, Chief Medical Officer of Catalyst, their presentations and symposium aim to clarify the therapeutic profile of AGAMREE® and its role in patient care. Catalyst's commitment to advancing robust research is vital for enhancing treatment outcomes for patients and their families.
The poster presentations will cover an array of topics related to vamorolone, including the use of concomitant cardiac medications, the association between glucocorticoid treatment duration and healthcare resource utilization, and delayed respiratory decline in DMD patients. Each presentation features collaborations with various experts from institutions such as Nationwide Children's Hospital and the Ann and Robert H. Lurie Children's Hospital of Chicago, reflecting a cohesive effort to understand and improve clinical management in DMD.
Additionally, the MDA Industry Forum will feature esteemed speakers like Dr. Craig McDonald from UC Davis Health and Dr. Leanne Ward from the University of Ottawa, focusing on advancing insights into DMD.
Catalyst Pharmaceuticals, headquartered in Coral Gables, Florida, emphasizes patient care and accessibility, striving to provide comprehensive support services. Their innovative approach has earned recognition, being listed among America’s Most Successful Companies and one of North America’s Fastest-Growing Companies. For more information, visit Catalyst’s official website.
MWN-AI** Analysis
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is making significant strides in the realm of Duchenne muscular dystrophy (DMD), evidenced by its recent announcements regarding real-world findings that will be showcased at the 2026 MDA Clinical & Scientific Conference. This focus on DMD positions Catalyst favorably within the biopharmaceutical landscape, particularly given the limited treatment options for rare diseases.
Investors should take note of Catalyst's commitment to advancing research on vamorolone, a novel corticosteroid aimed at improving patient outcomes in DMD. The company's poster presentations will delve into vital aspects of treatment efficacy and resource utilization, which are critical components for healthcare providers when prescribing therapies. The real-world analysis showcased at the conference may bolster the credibility of AGAMREE® and help solidify its role in clinical practice, thereby enhancing patient access.
Catalyst's strategic collaboration with Santhera Pharmaceuticals to host an MDA Industry Forum aims to deepen the understanding of DMD and, by extension, strengthen the company's reputation as a thought leader in the space. This initiative could drive interest from both clinical stakeholders and investors as they recognize the potential positive impact on patient care.
Given that Catalyst has been recognized by Forbes and Deloitte for its growth and success, it's likely that the company's strong performance will continue to attract attention. However, potential investors should remain cautious due to inherent risks associated with biopharmaceutical development, including regulatory approvals and market competition.
In conclusion, while Catalyst Pharmaceuticals presents a promising investment opportunity with its focus on DMD, investors should maintain a well-rounded approach, factoring in both the potential upside and the accompanying risks. Monitoring the outcomes of the conference and subsequent market response will be crucial for informed decision-making in this stock.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CORAL GABLES, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company will showcase real?world findings in Duchenne muscular dystrophy (DMD) through multiple poster presentations at the 2026 MDA Clinical & Scientific Conference in Orlando, Florida. Catalyst will also sponsor a vamorolone-focused MDA Industry Forum with Santhera Pharmaceuticals.
“The MDA meeting is a key opportunity to highlight the expanding real?world evidence shaping care for the Duchenne community,” said Will Andrews, MD, Chief Medical Officer of Catalyst. “Through our poster presentations and our sponsored symposium on long?term evidence generation, we’re contributing clinical insights that help clarify AGAMREE®’s profile and its role in patient care. Our commitment is to advance rigorous, meaningful research that moves the field forward for patients and their families.”
The poster presentations will focus on real-world analysis of vamorolone in patients living with DMD:
Poster Presentations:
Abstract Title: Real-world analysis of concomitant cardiac medication use with the novel corticosteroid vamorolone in patients with Duchenne muscular dystrophy (DMD)
Authors: Linda Cripe, MD, Nationwide Children's Hospital, Steven Woods, PharmD, Catalyst, Katherine Habkouk, PharmD, AnovoRx Specialty Pharmacy, Regina Grebla, PhD, Northeast Epi, LLC
Session Name: Poster Session
Topic: Clinical Management
Poster Number: 74 S
Date of Presentation: Sunday, March 8, 2026, 6:00 PM–8:00 PM ET
Abstract Title: Association Between Glucocorticoid Treatment Duration and Health Care Resource Utilization in Duchenne Muscular Dystrophy: A Real-World Analysis.
Authors: Steven Woods, PharmD, Catalyst Pharmaceuticals, Bridget McGowan, MD, Ann and Robert H. Lurie Children's Hospital of Chicago, Ashley Martin, PhD, BluePath Solutions, Alexa Gordon, MS, BluePath Solutions, Sana Mirza, MPH, BluePath Solutions, Paula Alvarez, MBA, MS, Rph, Critical Intelligence Consulting
Session Name: Poster Session
Topic: Other
Poster Number: 75 S
Date of Presentation: Sunday, March 8, 2026, 6:00 PM–8:00 PM ET
Abstract Title: Glucocorticoid Use and Delayed Respiratory Decline in Duchenne Muscular Dystrophy Patients: A Real-World Analysis
Authors: Steven Woods, PharmD, Catalyst Pharmaceuticals, Bridget McGowan, MD, Ann and Robert H. Lurie Children's Hospital of Chicago, Ashley Martin, PhD, BluePath Solutions, Alexa Gordon, MS, BluePath Solutions, Sana Mirza, MPH, BluePath Solutions, Paula Alvarez, MBA, MS, Rph, Critical Intelligence Consulting, Oscar Mayer, MD, The Children's Hospital of Philadelphia
Session Name: Poster Session
Topic: Other
Poster Number: 76S
Date of Presentation: Sunday, March 8, 2026, 6:00 PM–8:00 PM ET
MDA Industry Forum will highlight the latest insights from clinical leaders advancing our understanding of DMD:
Symposium:
Title: MDA Industry Forum Sponsored by Catalyst Pharmaceuticals in Conjunction With Santhera Pharmaceuticals
Speakers:
- Dr. Craig McDonald, MD, Chair, Department of Physical Medicine & Rehabilitation Professor, Departments of Pediatrics and Physical Medicine & Rehabilitation UC Davis Health, Sacramento, CA
- Dr. Leanne Ward, MD, Professor of Pediatrics, University of Ottawa, Ottawa, ON
Date of Presentation: Tuesday, March 10, 2026, 12:00 PM-1:30 PM ET
Location: Key Largo Room, The Hilton Orlando
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., has been recognized by Forbes as one of America’s Most Successful Company in 2023, 2024, and 2025, and on the 2025 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.
For more information, please visit Catalyst's website at www.catalystpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors described in Catalyst's Annual Report on Form 10-K for the 2025 fiscal year and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Contact Information:
Investor Contact
Melissa Kendis, Catalyst Pharmaceuticals, Inc.
(305) 420-3200
IR@catalystpharma.com
Media Contact
Ignacio Guerrero-Ros, Ph.D., Russo Partners, LLC
(646) 249-6817
Ignacio.Guerrero-Ros@russopartnersllc.com
FAQ**
How does Catalyst Pharmaceuticals Inc. CPRX plan to leverage the real-world findings presented at the MDA Clinical & Scientific Conference to enhance its portfolio in the rare disease sector, particularly for Duchenne muscular dystrophy?
2. What specific metrics will Catalyst Pharmaceuticals Inc. CPRX utilize to evaluate the impact of vamorolone in DMD patients based on the findings shared during the poster presentations?
3. In what ways does Catalyst Pharmaceuticals Inc. CPRX aim to expand its global footprint while maintaining its commitment to patient care as highlighted in the recent press release?
4. How does Catalyst Pharmaceuticals Inc. CPRX's recognition by Forbes and Deloitte reflect on its operational strategies and potential growth in the biopharmaceutical market, especially in rare diseases?
**MWN-AI FAQ is based on asking OpenAI questions about Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX).
NASDAQ: CPRX
CPRX Trading
3.93% G/L:
$24.62 Last:
224,352 Volume:
$24.10 Open:
